ICAS
PBYI icon

Investors Capital Advisory Services’s Puma Biotechnology PBYI Stock Holding History

Investors Capital Advisory Services’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000
Closed -$238K – 742
2014
Q3 		$238K Buy
+1,000
New +$205K 0.05% 510

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Investors Capital Advisory Services's PBYI Position: Q4 2014 in Review

Investors Capital Advisory Services sold out of Puma Biotechnology (PBYI) in Q4 2014, closing a stake of 1,000 shares — an estimated $238K sold.

Investors Capital Advisory Services first reported a position in PBYI in Q3 2014 and held it in 1 quarter. The position peaked at $238K in Q3 2014. 188 funds tracked by Wall St. Rank hold PBYI as of Q4 2014.

  • Investors Capital Advisory Services reported no remaining Puma Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Investors Capital Advisory Services sold 1,000 Puma Biotechnology shares in Q4 2014, an estimated $238K.
  • Investors Capital Advisory Services first reported a position in Puma Biotechnology in Q3 2014 and held it in 1 quarter.
  • Investors Capital Advisory Services's Puma Biotechnology position peaked at $238K in Q3 2014.
  • 188 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2014.

Based on Investors Capital Advisory Services's 13F filing for Q4 2014, filed 3 Feb 2015.